sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis

Sponsor
University of Aarhus (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT02702765
Collaborator
Aarhus University Hospital (Other)
33
1
1
72
0.5

Study Details

Study Description

Brief Summary

The aim is to investigate macrophage activation markers and correlations to liver fibrosis in patients with Wilsons Disease. Researchers wish to investigate associations to neurologic and metabolic liver function. Researchers will assess this by comparing blood samples with fibrosis and liver function analyses. This study provides new insight into macrophages and their involvement in Wilsons Disease.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Fibroscan
  • Procedure: Ultrasound
  • Drug: Galactose
  • Procedure: Liver biopsy
  • Procedure: Functional hepatic nitrogen clearance
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
33 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Macrophages and the Macrophage Activation Markers sCD163 and Mannose Receptor (sMR) in Patients With Wilsons Disease - Associations With Liver Disease Severity and Fibrosis
Actual Study Start Date :
Feb 1, 2016
Actual Primary Completion Date :
Feb 1, 2020
Anticipated Study Completion Date :
Feb 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Wilsons disease

All patients will receive all interventions (galactose elimination capacity test , ultrasound, fibroscan, continuous reaction time test and functional hepatic nitrogen clearance ), except liver biopsy.

Procedure: Fibroscan
Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver. The fibroscan is a non-invasive procedure

Procedure: Ultrasound
Ultrasound is a non-invasive procedure

Drug: Galactose
Galactose elimination capacity is performed to evaluate metabolic liver function. The metabolic liver function test galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours.
Other Names:
  • Galactose elimination capacity
  • Procedure: Liver biopsy
    Histological disease activity at time of diagnosis evaluating if any liver fibrosis

    Procedure: Functional hepatic nitrogen clearance
    Functional hepatic nitrogen clearance to evaluate metabolic liver function Functional hepatic nitrogen clearance requires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours

    Outcome Measures

    Primary Outcome Measures

    1. Measurement of the macrophage activation markers sCD163 [Baseline, 1 year, 2 year, 3 year]

      For the investigations a total of 100 ml of blood is drawn, all stored in a research biobank.

    2. Measurement of soluble mannose receptor (sMR) [Baseline, 1 year, 2 year, 3 year]

      For the investigations a total of 100 ml of blood is drawn, all stored in a research biobank.

    Secondary Outcome Measures

    1. Urinary copper excretion in 24 hour urine collection [Baseline, 1 year, 2 year, 3 year]

      The patient collects urine for 24 hours at home in a designated container, which is handed out at the department. The container is kept refrigerated and is brought to the control

    2. Ultrasound is performed for signs of liver cirrhosis. [Baseline, 1 year, 2 year, 3 year]

      Ultrasound is a non-invasive procedure. Signs og liver cirrhosis by ultrasound are surface modularity, a smaller liver, heterogeneous echo texture and signs of portal hypertension.

    3. Fibroscan is performed to evaluate liver stiffness (fibrosis) [Baseline, 1 year, 2 year, 3 year]

      Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver. The fibroscan is a non-invasive procedure.

    4. Continous Reaction Time to evaluate brain dysfunction [Baseline, 1 year, 2 year, 3 year]

      Continous Reaction Time is a computerized 10 minutes test that measures and combines motor reaction speed and sustained attention.

    5. Galactose elimination capacity is performed to evaluate metabolic liver function [Baseline, 1 year, 2 year, 3 year]

      The metabolic liver function test Galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours.

    6. Histological disease activity at time of diagnosis and liver biopsy, evaluating if any liver fibrosis [Baseline, 1 year, 2 year, 3 year]

      Liver fibrosis will be also be determined on liver biopsies.

    7. Functional hepatic nitrogen clearance to evaluate metabolic liver function [Baseline, 1 year, 2 year, 3 year]

      Functional hepatic nitrogen clearancerequires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours. It evaluates the metabolic liver function by measuring the clearance of alanine from blod by analyzing the amount og urea in the urine collected 4 hours after the start og the alanine infusion.

    8. The Portosystemic Encephalopathy to evaluate brain dysfunction [Baseline, 1 year, 2 year, 3 year]

      The Portosystemic Encephalopathy test is a 15-minute paper-pencil test battery comprised of 5 sub-tests: Digit Symbol test (DST), Number Connection Test A (NCT-A), Number Connection Test B (NCT-B), Serial Dotting Test (SDOT), and Line Tracing Test (LTT, time and errors).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 100 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • diagnosed with Wilsons disease
    Exclusion Criteria:

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Hepatology and Gastroenterology, Aarhus University Hospital Aarhus Denmark 8000

    Sponsors and Collaborators

    • University of Aarhus
    • Aarhus University Hospital

    Investigators

    • Principal Investigator: Henning Grønbæk, Professor, Aarhus University Hospital, Nørrebrogade 44, Aarhus C, Denmark, 8000

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Aarhus
    ClinicalTrials.gov Identifier:
    NCT02702765
    Other Study ID Numbers:
    • Wilson sCD163
    First Posted:
    Mar 9, 2016
    Last Update Posted:
    Apr 28, 2021
    Last Verified:
    Apr 1, 2021
    Keywords provided by University of Aarhus
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 28, 2021